CDT Equity Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CDT research report →
Price Chart
About the company
CDT Equity Inc. , a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.
- CEO
- Jamie Bligh
- IPO
- 2022
- Employees
- 4
- HQ
- Naples, FL, US
Get TickerSpark's AI analysis on CDT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $107.21K
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- -0.00
- Div Yield
- 0.00%
- Gross Margin
- 38.14%
- Op Margin
- 10.52%
- Net Margin
- 6.47%
- ROE
- 9.21%
- ROIC
- 84.73%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-36,757,000
- Net Income
- $-39,224,000-120.3%
- EPS
- $-11778.00+98.1%
- OCF Growth
- -60.7%
- FCF Growth
- -84.5%
- 52W High
- $291250.00
- 52W Low
- $0.22
- 50D MA
- $24.50
- 200D MA
- $20001.59
- Beta
- 1.69
- RSI (14)
- 15
- Avg Volume
- 943.59K
No earnings-call transcripts are available for CDT yet.
- Free Float
- 45.1%
- Shares Outstanding
- 466.14K
- Float Shares
- 210.39K
of shares held by institutions
9 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 688.81K | ▲ 517.23K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 22, 26 | Regan Andrew | other | 1,347,616 |
| Oct 23, 26 | Regan Andrew | other | 499,616 |
| Aug 28, 26 | Regan Andrew | sell | 29 |
| Aug 28, 26 | Regan Andrew | other | 543,683 |
| Jul 30, 26 | Regan Andrew | other | 5,436,830 |
| Aug 28, 26 | Regan Andrew | other | 543,683 |
| Oct 22, 26 | Manoira Corp | other | 0 |
| Aug 28, 26 | Regan Andrew | other | 5,436,830 |
| Aug 28, 26 | Regan Andrew | sell | 290 |
| Jul 30, 26 | Regan Andrew | other | 5,436,830 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CDT coverage
Recent articles, reports, and earnings notes.
No research on CDT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CDT report →CDT Notes Sarborg's Sale of Cryptocurrency Trading Agent
globenewswire.com · Nov 19
CDT Commences Human Skin Studies with QIMA Life Sciences on Novel Tapinarof Combinations in Vitiligo
globenewswire.com · Nov 11
CDT Equity Welcomes U.S. Regulatory Development Supporting Expanded Access to Compounded Peptides
globenewswire.com · Oct 30
CDT Partners with Manoira to Explore Enhancing Animal Health Products Ahead of Launch
globenewswire.com · Oct 27
CDT Highlights Sarborg's Solid-Form Patent Filing on a First-in-Class Respiratory Asset
globenewswire.com · Oct 14
CDT Highlights Sarborg's Expanding Quantum Computing IP Portfolio and Application to Drug Discovery
globenewswire.com · Sep 29
CDT Equity Inc. Announces Reverse Stock Split
globenewswire.com · Sep 25
CDT Partners with QIMA Life Sciences to Evaluate Novel Tapinarof Combinations in Psoriasis and Vitiligo
globenewswire.com · Sep 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.